KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm. 2024;38(4):137-144 / www.klinickafarmakologie.cz 144 PŮVODNÍ PRÁCE Prínos inovatívnej terapie u pacientov s cystickou fibrózou LITERATÚRA 1. Kayserová H, et al. Štandardné diagnostické, terapeutické postupy pre pacientov s cystickou fibrózou. Ministerstvo zdravotníctva SR. 2021. 2. Národné centrum zdravotníckych informácií. Tlačová správa zo dňa 21. novembra 2024: Európsky deň cystickej fibrózy. NCZI 2024. [on-line]. cit. 26-11-2024. Available from: https:// www.nczisk.sk/Documents/aktuality/tlacove_spravy/2024/ TS_Europsky_den_cystickej_fibrozy_22112024.pdf. 3. Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Model Exp Med. 2021;4(3):220-232. 4. Kayserová H. Cystická fibróza (1. časť). Via pract. 2007;4(3): 128-132. 5. Giertlová M, Šprincová A. Diagnostika cystickej fibrózy so zameraním na molekulárno-genetickú analýzu CFTR génu. News lab. 2018;9(2):98-101. 6. Vávrová V, et al. Centra CF Motol. Cystická fibróza – příručka pro nemocné, jejich rodiče a přátelé. Personal publishing, 2000. 7. Zolin A, Adamoli A, Bakkeheim E, van Rens J, et al. ECFSPR Annual Report 2022, 2024. [Internet]. Available from: www. ecfs.eu/ecfspr. 8. Elbourn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519-2531. 9. Dave S, Honney S, Raymond J, et al. An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis. 2005; 45(3):e41-e44. 10. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 2007;62(4):360-367. 11. Jankova I. Cystická fibróza. Bakalářska práce. Brno: Masarykova univerzita, Lékařská fakulta; 2008. 59 s. 12. Juřica J. Moderní terapie kašle. Prakt. lékáren. 2013;9(6): 219-224. 13. Kayserová H. Cystická fibróza (2. časť). Via pract. 2007; 4(4):189-191. 14. Available from: https://pari-inhalatory.sk/pari-o-pep. 15. Available from: https://mr-diagnostic.cz/simeox. 16. Castellani C, Duff AJA, Bell SC, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-178. 17. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory therapy for cystic fibrosis. Cochrane Database Syst Rev 2007;4. https://doi.org/10.1002/14651858.CD001505.pub2. 18. Konstan MW, Butler SM, Wohl ME, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr. 2003;142(6):624-630. 19. Fila L. Cystická fibróza dospělých. Vnitř Lék. 2017;63(11): 834-842. 20. Popescu SC. Farmakoekonomický rozbor lieku. Ministerstvo zdravotníctva Slovenskej republiky. 2023. 21. Ramsey BW, Davies J, McElvaney NG, et al. VX08–770–102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672. 22. Súhrn charakteristických vlastností lieku Kaftrio. ŠUKL. 2024. 23. Middleton PG, Mall MA, Drevinek P, et al. ElexacaftorTezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. 24. Súhrn charakteristických vlastností lieku Symkevi. ŠUKL. 2023. 25. Pettit RS, Fellner C. CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014;39(7):500-511. 26. Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, et al. The pharmacokinetics of antibiotics in cystic fibrosis, Expert Opinion on Drug Metabolism & Toxicology. 2021;17(1):53-68. 27. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12(4):318-331. 28. Highlights report ECFSPR. 2022. [on-line]. Available from: www.ecfs.eu/ecfspr. 29. Švihovec J, et al. Farmakologie. 1. vyd. Praha: Grada Publishing, a. s.; 2018. 1008 s. 30. Barry PJ, Mall MA, Alvarez A, et al. Triple Therapy for Cystic Fibrosis Phe508del-Gating and – Residual Function Genotypes. N Engl J Med. 2021;385(9):815-825. 31. Zemanick ET, Taylor-Cousar JL, Davies J, et al. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021;203(12):1522-1532. 32. Heroutová M. Fyzioterapia pre dospelých pacientov s diagnózou CF. CF Plus Motýlik. Košice: Slovenská asociácia cystickej fibrózy. 2010;3(6):22. 33. Ratjen F, Hug C, Marigowda G, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017;5(7):557-567. 34. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-1948. 35. Ledder O, Haller W, Couper RT, et al. Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations. J Gastroenterol Hepatol. 2014;29(12):1954-1962. 36. Chillón M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332(22):1475-1480. 37. Bower JK, Volkova N, Ahluwalia N, et al. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. Journal of Cystic Fibrosis. 2023;22(4):730-737.
RkJQdWJsaXNoZXIy NDA4Mjc=